A new orally effective targeted therapy for the treatment of non-small cell lung cancer (NSCLC) has been approved by the FDA. Crizotinib is a receptor tyrosine kinase inhibitor including anaplastic lymphoma kinase (ALK). Go Back
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.